Search

Your search keyword '"Rodríguez-Avial I"' showing total 123 results

Search Constraints

Start Over You searched for: Author "Rodríguez-Avial I" Remove constraint Author: "Rodríguez-Avial I"
123 results on '"Rodríguez-Avial I"'

Search Results

1. Adult T-cell leukemia/lymphoma in HTLV-1 non-endemic regions

2. Screening for HTLV-1 infection should be expanded in Europe

3. HTLV-1-associated myelopathy in Spain

4. HTLV-1 infection among Latin American pregnant women living in Spain

5. Adult T-cell leukemia/lymphoma in HTLV-1 non-endemic regions

9. Service-Learning, Movies, and Infectious Diseases: Implementation of an Active Educational Program in Microbiology as a Tool for Engagement in Social Justice

11. Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain

13. Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain

17. Useful independent factors for distinguish infection and colonization in patients with urinary carbapenemase-producing Enterobacteriaceae isolation

21. In Vitro Activities of Tigecycline against Erythromycin-Resistant Streptococcus pyogenesand Streptococcus agalactiae: Mechanisms of Macrolide and Tetracycline Resistance

23. [Update in Infectious Diseases 2016]

24. Rapid subacute myelopathy following kidney transplantation from HTLV-1 donors: role of immunosuppresors and failure of antiretrovirals

26. Efficacy of delafloxacin alone and in combination with cefotaxime against cefotaxime non-susceptible invasive isolates of Streptococcus pneumoniae.

28. Evolution of antibody titers after two doses of mRNA Pfizer-BioNTech vaccine and effect of the third dose in nursing home residents.

29. Resistance to fosfomycin is increasing and is significantly associated with extended-spectrum β-lactamase-production in urinary isolates of Escherichia coli.

30. Negative effect of the second dose of the BNT162b2 vaccine in a significant percentage of individuals with previous COVID infection.

31. Identification of CRF66_BF, a New HIV-1 Circulating Recombinant Form of South American Origin.

32. Author Correction: Identification of CRF89_BF, a new member of an HIV-1 circulating BF intersubtype recombinant form family widely spread in South America.

33. Identification of CRF89_BF, a new member of an HIV-1 circulating BF intersubtype recombinant form family widely spread in South America.

34. [Usefulness of MALDI-TOF and REP-PCR against PFGE for the epidemiological study of Acinetobacter baumannii].

35. Panuveitis and Optic Neuritis as a Possible Initial Presentation of the Novel Coronavirus Disease 2019 (COVID-19).

36. Synergy of Linezolid with Several Antimicrobial Agents against Linezolid-Methicillin-Resistant Staphylococcal Strains.

37. Increase of serotype 8, ST53 clone, as the prevalent strain of Streptococcus pneumoniae causing invasive disease in Madrid, Spain (2012-2015).

38. Comparative evaluation of plazomicin MICs obtained using agar dilution versus broth microdilution methods and impact of inoculum size against ESBL-producing Escherichia coli, carbapenemase-producing Klebsiella pneumoniae and methicillin-resistant Staphylococcus aureus clinical isolates.

39. Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain.

40. Identification of Streptococcus pneumoniae lytA, plyA and psaA genes in pleural fluid by multiplex real-time PCR.

41. In-vitro activity of several antimicrobial agents against methicillin-resistant Staphylococcus aureus (MRSA) isolates expressing aminoglycoside-modifying enzymes: potency of plazomicin alone and in combination with other agents.

42. Detection of Escherichia coli ST131 clonal complex (ST705) and Klebsiella pneumoniae ST15 among faecal carriage of extended-spectrum β-lactamase- and carbapenemase-producing Enterobacteriaceae.

43. Plazomicin Activity against 346 Extended-Spectrum-β-Lactamase/AmpC-Producing Escherichia coli Urinary Isolates in Relation to Aminoglycoside-Modifying Enzymes.

44. [Update in Infectious Diseases 2016].

45. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.

46. Can Plazomicin Alone or in Combination Be a Therapeutic Option against Carbapenem-Resistant Acinetobacter baumannii?

47. Characterization of Inhibitor-Resistant TEM β-Lactamases and Mechanisms of Fluoroquinolone Resistance in Escherichia coli Isolates.

48. Carbapenemase-producing Enterobacteriaceae in a tertiary hospital in Madrid, Spain: high percentage of colistin resistance among VIM-1-producing Klebsiella pneumoniae ST11 isolates.

49. Rapid diagnosis of invasive pneumococcal disease in pediatric population.

50. [Increasing prevalence of fosfomycin resistance in extended-spectrum-beta-lactamase-producing Escherichia coli urinary isolates (2005-2009-2011)].

Catalog

Books, media, physical & digital resources